Peter Schafer

Peter Schafer

Company: Translational Medicine, Bristol Myers Squibb

Job title: Executive Director


Peter Schafer is currently Executive Director and Head of the Immunology, Cardiovascular, and Fibrosis Translational Development Disease Team within the Translational Medicine department at BMS. During his 20 years at Celgene Corporation, Peter contributed as co-inventor of apremilast (Otezla®), now approved for psoriasis, psoriatic arthritis, and Behçet’s Disease, with a driving role in its discovery, nonclinical and clinical development, regulatory approval, and life cycle management. He was part of the drug discovery team that uncovered the mechanism of action of the IMiDs® compounds lenalidomide (Revlimid®) and pomalidomide (Pomalyst®) as targeting the cereblon substrates Ikaros and Aiolos, assisted in their regulatory approval for myelodysplastic syndrome and multiple myeloma, and also brought iberdomide into clinical development for the treatment of lupus. Peter has been co-leading the PROLIFIC prognostic lung fibrosis consortium since 2018.

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.